Introduction
Infection and related sepsis/septic shock are the most common causes of acute kidney injury (AKI) in ICU patients. It is associated with a high (up to 60%) in-hospital mortality. The mortality associated with the combination of sepsis and AKI is significantly higher compared with AKI alone. 1, 2 Therefore, as with all other interventional measures, an early and appropriate antibiotic regimen is important for improving patient outcomes. Renal replacement therapy (RRT) is an integral part of the management of AKI in critically ill patients. Although continuous RRT (CRRT) is commonly employed, hybrid techniques, including sustained low-efficiency dialysis/diafiltration (SLED/SLED-f), also known as slow lowefficiency dialysis and extended daily dialysis/diafiltration (EDD/EDD-f), are being used because of their practical advantages and cost savings over CRRT with similar haemodynamic stability and no difference in mortality. 3, 4 SLED-f was developed as an intermediate mode of therapy between CRRT and intermittent haemodialysis (IHD). SLED-f is typically used for only 6-12 h per day, although rarely some units employ it as a continuous modality. 4 However, these advantages present a new set of challenges for drug dosing owing to variations in CL during and after SLED-f because of its intermittent nature. Drug dosing studies have been conducted on ,20% of the currently used drugs in CRRT and ,1% of the hybrid techniques. [4] [5] [6] This is further complicated by the pathophysiological changes and related pharmacokinetic (PK) and pharmacodynamic (PD) variation in critically ill patients. 7 Piperacillin is a b-lactam penicillin antibiotic commonly used for the empirical therapy of sepsis and other hospital-acquired infections in critically ill patients. Renal elimination of piperacillin accounts for $50%-60% of the dose administered and involves glomerular filtration and tubular secretion. 8 Although dosing requirements for piperacillin/tazobactam have been relatively well established in CRRTs, the dosages required to attain the PD targets during SLED-f have not been established. 9 The objective of the study was to describe the PK of piperacillin during SLED-f and compare the results with those reported in other forms of RRT. This was a prospective, open-labelled PK study conducted at the ICU of The Queen Elizabeth Hospital (Adelaide, Australia). Critically ill patients who met the following criteria were enrolled after obtaining written informed consent either from the patient or the patient's legally authorized representative: (i) receiving piperacillin in combination with tazobactam; (ii) age !18 years; (iii) present in ICU and undergoing/planning to undergo SLED-f; (iv) arterial line in situ or planned insertion; and (v) indwelling urinary catheter in situ or planned insertion. Patients who met one or both of the following criteria were excluded: (i) known or suspected allergy to penicillin agents; and (ii) pregnancy.
Methods

Ethics
Piperacillin/tazobactam administration and sample collection
Piperacillin in combination with tazobactam was initiated at the discretion of the treating physician based on the clinical requirement. Piperacillin (4 g) was administered in combination with tazobactam as an intravenous infusion over 30 min. Sampling occurred during two dosing intervals: one during SLED-f and another without SLED-f. Piperacillin/tazobactam was administered 30 min prior to initiation of SLED-f when sampling with SLED-f. Blood samples were collected at pre-and post-filter ports within the SLED-f circuit during SLED-f and from an arterial catheter during sampling without SLED-f. Blood samples were collected before initiation of the infusion and at 30, 60, 120, 180, 240, 300 and 360 min post-commencement of the infusion. Ultrafiltration samples could not be collected owing to use of an online water inlet and outlet system common to SLED-f circuitry.
SLED-f was performed in all patients using a 4008S haemodialysis machine (Fresenius Medical Care, Bad Homburg, Germany) with an AV600S polysulphone ultra-flux filter (1.4 m 2 surface area, Fresenius Medical Care, Bad Homburg, Germany). A standardized prescription consisted of haemodiafiltration with a target duration of 6-8 h (with 12 L/h blood and dialysate flow and 4 L/h pre-dilution). Data on the precise times for SLED-f commencement and cessation, owing to blood clotting on the filter or the end of treatment, were recorded. Plasma concentrations of piperacillin were analysed with a previously validated HPLC system with an electrospray mass spectrometer detector (LC/MS-MS) (AB Sciex Pty Ltd API3200; Shimadzu HPLC, Kyoto, Japan).
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PK and statistical analysis
Non-compartmental PK analysis of the data was performed. C max and T max after drug administration were obtained directly by visual examination of concentration-time data. The terminal K el was estimated from the slope of the terminal exponential phase of the logarithmic plasma concentrationtime profile, and t1 =2 was determined as 0.693/K el . CL was determined as dose/plasma AUC 0-1 . The amount of piperacillin removed owing to SLED-f was estimated from concentrations before (C in ) and directly after (C out ) the SLED-f filter: (Q in ÁC in # Q out ÁC out )/C in , where plasma flows in (Q in ) and out (Q out ) of the dialyser were estimated using the blood flow, haematocrit and ultrafiltration rate. The Mann-Whitney U-test was used to compare the PK parameters with and without SLED-f using GraphPad Prism version 7.00 for Windows (GraphPad Software, La Jolla, CA, USA; www.graphpad.com) and P , 0.05 was considered to be statistically significant.
Results
Six AKI patients with anuria (urine output ,100 mL) and sepsis were recruited. Sampling occurred in six patients during SLED-f and in five patients without SLED-f. In all patients sampling occurred at least 2 days after treatment initiation with piperacillin/ tazobactam. All six patients received SLED-f for 6 h with a total fluid removal of 2.08+0.92 L. The total effluent flow achieved in this study was 16.36+0.18 L/h. The cumulative fluid balance was positive (6.30+3.90 L). All patients received 12 hourly piperacillin dosing except one who received 24 hourly piperacillin. Tables 1 and 2 describe the demographic and clinical characteristics of the subjects and the PK parameter estimates for piperacillin with and without SLED-f, respectively. A statistically significant difference (P , 0.05) was observed for CL and t1 =2 with and without SLED-f. We compared the PK parameters observed in this study against the published data for piperacillin in other RRTs (Table 3) . 8, [11] [12] [13] [14] Fifty-eight percent of piperacillin was cleared by SLED-f during the 6 h treatment.
Discussion
To the best of our knowledge, this is the first report of piperacillin PK during SLED-f in critically ill patients. Piperacillin is widely used in critically ill patients and yet information on the effect of SLED-f on its dosing requirements is lacking. Although limited data are available from IHD studies in end-stage renal disease patients, 12 ,15 Sinnollareddy et al.
these cannot be directly extrapolated to SLED-f, particularly in the context of critical illness owing to longer RRT treatment times, frequency of treatment, filter types, blood flow rates, dialysate flow rates and the additional ultrafiltration component. The data from this report also indicate that the amount of removal by the filter and CL could differ from that of IHD. It was reported that $30%-45% of the administered piperacillin dose was eliminated during one IHD session (3.5 h) in patients with end-stage renal disease 12,15 compared with 58% observed in our study ( Table 2 ). The longer treatment time (3.5 versus 6 h), possibly higher-efficiency dialyser and additional component of filtration (effluent) rate could explain the higher piperacillin removal observed in this study. A statistically significant correlation was observed between effluent flow rate and piperacillin total CL during CRRTs in a regression analysis of published PK data. 16 This suggests that the dose recommended for IHD and other RRT techniques could lead to suboptimal dosing in patients receiving SLED-f.
CL during RRT, t1 =2 and AUC obtained from this study were comparable with those reported in the post-dilution mode of continuous veno-venous haemodiafiltration (CVVHDF) studies (Table 3) . 8, [11] [12] [13] [14] This demonstrates that although the drug CL per unit of time is greater during SLED-f, the shorter duration of therapy means that drug CL over 24 h is comparable for both modalities. Importantly, this study cannot provide definitive dosing guidance owing to small patient numbers, but we hypothesize that piperacillin could be dosed as in patients receiving CVVHDF (every 8 h) . 17 However, it should be noted that, as in CRRT, piperacillin CL in patients receiving SLED-f will neither be constant nor predictable because of higher CL during SLED-f and potentially impaired CL when not receiving SLEDf. Therefore, it is important to pay attention to residual renal function, which could increase the total CL of piperacillin along with the CL observed during SLED-f and the duration of SLED-f. Knowledge of these issues can help procure appropriate doses and timing of these doses relative to use of SLED-f. Another important factor to consider is that some ICUs use SLED-f for up to 12 h or potentially in a continuous mode, in which the amount of piperacillin eliminated by SLED-f treatment will be higher than reported in this study. Accordingly, in such circumstances alternative dose/dosing strategies would be required.
The observed mean V ss was higher than reported in healthy volunteers (27 versus 15 L), but similar to that reported in patients with severe sepsis (27 versus 25 L) ( Table 3) . Observed t1 =2 , CL and AUC without SLED-f were more than double the values observed during SLED-f, consistent with the fraction of piperacillin (58%) cleared during SLED-f. The observed median C min was higher than the EUCAST clinical breakpoints for Enterobacteriaceae and Piperacillin pharmacokinetics in extended diafiltration JAC Pseudomonas aeruginosa (16 mg/L). 18 However, it should be noted that there were considerable inter-individual differences with observed C min , with two of the six patients achieving a C min ,16 mg/L towards the end of the 6 h duration of the SLED-f (measured C min was 13 and 5 mg/L in these two patients).
Based on the observed C min and amount of piperacillin removed by SLED-f (58%), a maintenance dose of at least 4 g every 12 h with at least a 2 g replacement dose post-SLED-f or 4 g every 8 h would be a reasonable approach to piperacillin dosing in ICU patients with anuria and sepsis receiving SLED-f with a duration similar to the current study until these are validated using a relatively larger sample size supplemented by population PK analysis and associated dosing simulations. In centres where SLED-f is used for longer than in this study (6 h) or used continuously with settings similar to those used in this study, alternative dosing strategies, i.e. extended infusion/continuous infusion and/or therapeutic drug monitoring, would be required to avoid sub-optimal concentrations during SLED-f.
